Featured Press Releases

Applications Are Being Accepted by the Vilcek Foundation from Immigrants Working in Biomedical Science

Applications Are Being Accepted by the Vilcek Foundation from Immigrants Working in Biomedical Science

New EpiVax Study Uncovers the Role of Treg Epitopes (Tregitopes) in Antibody Maturation: Implications for Therapeutic Antibodies

New EpiVax Study Uncovers the Role of Treg Epitopes (Tregitopes) in Antibody Maturation: Implications for Therapeutic Antibodies

  • 22 Apr 2025

EpiVax, Inc. announces a new study published in Frontiers in Immunology unveiling the impact of...

Algiax Pharmaceuticals expands AP-325 study in chronic neuropathic pain, adds 12 sites in Belgium and France

Algiax Pharmaceuticals expands AP-325 study in chronic neuropathic pain, adds 12 sites in Belgium and France

Cytonics Begins First-In-Human Phase 1 Clinical Study for CYT-108 in Osteoarthritis Knee Patients

Cytonics Begins First-In-Human Phase 1 Clinical Study for CYT-108 in Osteoarthritis Knee Patients

Lipella Pharmaceuticals initiates Phase 2a trial for LP-310 in oral lichen planus, enrolling the first patients

Lipella Pharmaceuticals initiates Phase 2a trial for LP-310 in oral lichen planus, enrolling the first patients

Space Cargo Unlimited and Exobiosphere Partner for High-Throughput Space Biotech

Space Cargo Unlimited and Exobiosphere Partner for High-Throughput Space Biotech

Spruce Biosciences Reports Long-Term Data Showing Efficacy and Safety of Tralesinidase Alfa in Sanfilippo Syndrome Type B

Spruce Biosciences Reports Long-Term Data Showing Efficacy and Safety of Tralesinidase Alfa in Sanfilippo Syndrome Type B

  • Spruce Biosciences, Inc.
  • 18 Aug 2025
Izalontamab Brengitecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

Izalontamab Brengitecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

  • SystImmune, Inc.
  • 18 Aug 2025
New Survey Shows Pediatricians Strongly Prefer Genexa’s Ingredients Over Leading Children’s Tylenol® Products

New Survey Shows Pediatricians Strongly Prefer Genexa’s Ingredients Over Leading Children’s Tylenol® Products

  • Genexa
  • 15 Aug 2025
Proving the strength of its drug-delivery platform, the Daewoong Therapeutics Microneedle Patch achieves best-in-class bioavailability

Proving the strength of its drug-delivery platform, the Daewoong Therapeutics Microneedle Patch achieves best-in-class bioavailability

  • Daewoong Therapeutics Inc
  • 13 Aug 2025
Abcentra LLC Commences Phase 2b

Abcentra LLC Commences Phase 2b 'FORTIFY' Trial with First Patient Dosed, Evaluating Orticumab for Cardiovascular Disease

  • Abcentra
  • 12 Aug 2025
Viatris announces the approval of the first generic iron sucrose injection in the U.S

Viatris announces the approval of the first generic iron sucrose injection in the U.S

  • Viatris Inc.
  • 11 Aug 2025
Webinar: Leverage AI for Operational Excellence and Strategic Cost Management

Most Popular
August   2025
M T W T F S S
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

User Area

Discover

Engage with Us

© 2024 Pharmaceutical Era — A product of HISSM. All Rights Reserved.